Improving the benchmark for measuring disease modification and reducing the use of symptomology is imperative for addressing underserved areas in women’s health such as ovarian cancer and endometriosis. This panel discussion will deep dive into the importance of prioritizing research through a sex & gender lens to identify new molecules, exploring the challenges and opportunities in investing in early-stage research, partnering with research institutions, and considering what more can be done.
Speaker(s):
![](https://ent-gen-ai-summit-west.com/sites/default/files/styles/panopoly_image_square/public/speakers/headshot_214.jpg?itok=9-_uoD6Y&c=97827043442310bbc086799bd258afe5)
Oriana Papin-Zoghbi
CEO & Co-Founder
AOA Dx
![](https://ent-gen-ai-summit-west.com/sites/default/files/styles/panopoly_image_square/public/speakers/sandy_milligan_updated_headshot_1.jpg?itok=8lGk24IQ&c=be5c9e12c869438530eb4d5ce29453e3)
Sandy Milligan, MD, JD
President, Research & Development, Laboratory Operations, IT and HR
Aspira Women's Health
![](https://ent-gen-ai-summit-west.com/sites/default/files/styles/panopoly_image_square/public/speakers/primavera_spagnolo.jpg?itok=4vGOshZw&c=5f0b0a244406b1e7f31f9fd01ce5bc83)
Primavera Spagnolo, MD, PhD
Scientific Director, Connors Center for Women’s Health and Gender Biology
Brigham and Women’s Hospital